Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors

IntroductionPD-(L)1 inhibitors (IO) have improved the prognosis of non-small-cell lung cancer (NSCLC), but more reliable predictors of efficacy and immune-related adverse events (irAE) are urgently needed. Cytokines are important effector molecules of the immune system, whose potential clinical util...

Descrición completa

Detalles Bibliográficos

Principais autores:	Hannah Schindler, Fabienne Lusky, Lea Daniello, Mariam Elshiaty, Lena Gaissmaier, Karolina Benesova, Margarida Souto-Carneiro, Arlou Kristina Angeles, Florian Janke, Florian Eichhorn, Daniel Kazdal, Marc Schneider, Stephan Liersch, Sarah Klemm, Paul Schnitzler, Albrecht Stenzinger, Holger Sültmann, Michael Thomas, Petros Christopoulos
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Oncology
Assuntos:	immune-checkpoint inhibitors immunotherapy immune-related adverse events lung cancer biomarker cytokines
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1010660/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!